Stockscreener 앱 받기
9.77
0.31%
-0.03
시장 영업 전:
9.83
0.06
+0.61%
전일 마감가:
$9.80
열려 있는:
$9.78
하루 거래량:
661.52K
Relative Volume:
0.54
시가총액:
$713.09M
수익:
-
순이익/손실:
$-86.60M
주가수익비율:
-3.4494
EPS:
-2.8324
순현금흐름:
$-67.37M
1주 성능:
+4.49%
1개월 성능:
+6.08%
6개월 성능:
+138.88%
1년 성능:
+37.03%
1일 변동 폭
$9.475
$10.02
1주일 범위
$9.12
$10.02
52주 변동 폭
$1.45
$10.38
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
명칭
Lexeo Therapeutics Inc
전화
(212) 547-9879
주소
345 PARK AVENUE SOUTH, NEW YORK
LXEO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
9.77 | 715.28M | 0 | -86.60M | -67.37M | -2.8324 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-10-15 | 개시 | Guggenheim | Buy |
| 2025-07-31 | 개시 | Oppenheimer | Outperform |
| 2024-06-13 | 개시 | Robert W. Baird | Outperform |
| 2024-06-06 | 개시 | H.C. Wainwright | Buy |
| 2023-11-28 | 개시 | Chardan Capital Markets | Buy |
| 2023-11-28 | 개시 | JP Morgan | Overweight |
| 2023-11-28 | 개시 | Leerink Partners | Outperform |
| 2023-11-28 | 개시 | RBC Capital Mkts | Outperform |
| 2023-11-28 | 개시 | Stifel | Buy |
모두보기
Lexeo Therapeutics Inc 주식(LXEO)의 최신 뉴스
Janus Henderson Group PLC Expands Stake in Lexeo Therapeutics Inc - GuruFocus
Aug Wrap: Will Lexeo Therapeutics Inc stock benefit from AI adoptionStock Surge & Smart Allocation Stock Reports - moha.gov.vn
Lexeo Therapeutics (NASDAQ:LXEO) Receives “Buy” Rating from Chardan Capital - Defense World
Aug Action: What sentiment indicators say about Lexeo Therapeutics Inc stock - moha.gov.vn
Lexeo Therapeutics' (LXEO) Buy Rating Reaffirmed at Chardan Capital - MarketBeat
Lexeo Therapeutics (LXEO) Rating Maintained as 'Buy' by Chardan Capital | LXEO Stock News - GuruFocus
Oppenheimer reiterates Outperform rating on Lexeo Therapeutics stock By Investing.com - Investing.com Canada
Lexeo Therapeutics stock holds Overweight rating as Cantor sees PKP2-ACM potential - Investing.com Canada
Check Out Lexeo Therapeutics Inc (LXEO)’s Trade Data Rather Than the Analysts’ Views - setenews.com
Update Recap: Will Lexeo Therapeutics Inc stock benefit from AI adoptionJuly 2025 Fed Impact & Consistent Growth Equity Picks - moha.gov.vn
Portfolio Update: Why Lexeo Therapeutics Inc stock remains resilientJuly 2025 Review & Real-Time Buy Signal Notifications - moha.gov.vn
How resilient is Lexeo Therapeutics Inc. stock in market downturnsTreasury Yields & Fast Entry High Yield Stock Tips - Newser
Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum - marketscreener.com
Lexeo Therapeutics to Host Virtual Key Opinion Leader Event - GlobeNewswire
Why Lexeo Therapeutics Inc. stock remains resilientWeekly Stock Summary & Accurate Buy Signal Alerts - Newser
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Trading Down 7.8%What's Next? - MarketBeat
A look into Lexeo Therapeutics Inc (LXEO)’s deeper side - setenews.com
Lexeo Therapeutics (NASDAQ:LXEO) Now Covered by Analysts at Cantor Fitzgerald - MarketBeat
Lexeo Therapeutics stock undervalued, Cantor Fitzgerald reiterates $19 target By Investing.com - Investing.com Canada
Will Lexeo Therapeutics Inc. stock deliver shareholder valueExit Point & Consistent Income Trade Ideas - moha.gov.vn
Why Lexeo Therapeutics Inc. stock is a must watch in 2025July 2025 Patterns & Expert Approved Momentum Ideas - BỘ NỘI VỤ
Paradigm Biocapital Advisors LP Acquires Significant Stake in Le - GuruFocus
LXEO Stock Price and Chart — NASDAQ:LXEO - TradingView
Research Analysts Set Expectations for LXEO FY2025 Earnings - Defense World
Savant Capital LLC Invests $119,000 in Lexeo Therapeutics, Inc. $LXEO - MarketBeat
Insider Selling: Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells 1,127 Shares of Stock - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Coverage Initiated at Cantor Fitzgerald - MarketBeat
Adler, Lexeo Therapeutics CMO, sells $5.7k in LXEO stock By Investing.com - Investing.com Australia
Lexeo Therapeutics CEO Makes Significant Stock Sale! - TipRanks
Balyasny Asset Management L.P. Increases Stake in Lexeo Therapeu - GuruFocus
[Form 4] Lexeo Therapeutics, Inc. Insider Trading Activity - Stock Titan
Adler, Lexeo Therapeutics CMO, sells $5.7k in LXEO stock - Investing.com
Lexeo Therapeutics CEO Sells Shares to Cover Tax Obligations - TradingView
CEO Townsend Surrenders 1,127 Of Lexeo Therapeutics Inc [LXEO] - TradingView
Cantor Fitzgerald Initiates Coverage on Lexeo Therapeutics With Overweight Rating, $19 Price Target - MarketScreener
Equities Analysts Set Expectations for LXEO FY2025 Earnings - MarketBeat
HC Wainwright Has Optimistic Outlook of LXEO FY2025 Earnings - Defense World
Lexeo Therapeutics Stock Rallies On Discussions With FDA To Expedite Friedreich’s Ataxia Drug Approval Process - MSN
Real time pattern detection on Lexeo Therapeutics Inc. stockMarket Activity Recap & Precise Entry and Exit Recommendations - newser.com
Using Ichimoku Cloud for Lexeo Therapeutics Inc. technicalsWeekly Market Summary & Real-Time Volume Triggers - newser.com
Will Lexeo Therapeutics Inc. price bounce be sustainableGold Moves & Daily Entry Point Alerts - newser.com
Using data models to predict Lexeo Therapeutics Inc. stock movementQuarterly Trade Review & Reliable Entry Point Alerts - newser.com
Officer Tai Files To Sell 386 Of Lexeo Therapeutics Inc [LXEO] - TradingView
Institutional Investors Are Lexeo Therapeutics, Inc.'s (NASDAQ:LXEO) Biggest Bettors and Were Rewarded After Last Week's US$70m Market Cap Gain - 富途牛牛
Lexeo Therapeutics Insiders Benefitted From Selling Stock At US$7.01 - simplywall.st
Optimistic Buy Rating for Lexeo Therapeutics Driven by High-Dose Potential and Superior Safety Profile - TipRanks
V2Y Corporation Ltd Expands into Renewable Energy and Commodities - The Globe and Mail
Can Lexeo Therapeutics Inc. stock withstand economic slowdownWeekly Trend Summary & Stock Portfolio Risk Management - newser.com
Lexeo Therapeutics Inc (LXEO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Lexeo Therapeutics Inc 주식 (LXEO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Adler Eric | Chief Medical Officer |
Nov 18 '25 |
Sale |
9.27 |
615 |
5,701 |
72,646 |
| See Tai Sandi | Chief Development Officer |
Nov 18 '25 |
Sale |
9.27 |
386 |
3,578 |
65,476 |
| Robertson Jenny | Chief Legal Officer |
Nov 18 '25 |
Sale |
9.27 |
549 |
5,089 |
68,381 |
| Otero Jose Manuel | Chief Technical Officer |
Aug 18 '25 |
Sale |
9.27 |
721 |
6,684 |
63,476 |
1.08%
0.91%
자본화:
|
볼륨(24시간):